American Vanguard reported a decrease in net sales and net income for Q1 2023 compared to Q1 2022, primarily due to supply chain disruptions and a glut of generic herbicides affecting domestic crop product sales. Despite the setback, the company reaffirms its double-digit full-year 2023 EBITDA growth target, anticipating stronger performance in the second half of the year.
Q1 2023 net sales decreased to $124.89 million from $149.59 million in Q1 2022.
Q1 2023 net income declined to $1.92 million from $9.94 million in Q1 2022.
The company experienced supply chain delays that impacted production and sales of its leading corn soil insecticide, Aztec®.
American Vanguard anticipates higher sales of US crop products in the second half of 2023 due to low inventories in the distribution channel.
American Vanguard expects to achieve higher adjusted EBITDA (between $84MM - $86MM) than in 2022, despite a first quarter setback arising from delays in restarting our supply chain, which is now back at capacity.
Visualization of income flow from segment revenue to net income